Intelligence / Healthtech / De Novo Grants / Essilor Of America, Inc.
Approvalsnovel device granted (FDA De Novo)25 Sept 2025
Essilor Of America, Inc.
25 Sept 2025: Novel device granted (FDA De Novo) · Essilor® Stellest®. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 25 Sept 2025
- Device
- Essilor® Stellest®
- Specialty
- Ophthalmic
- Product Code
- QUR
- Country
- United States
- Location
- Dallas, TX
- Submitted
- 2025-04-28
- Reference
- DEN250016
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Essilor Of America, Inc.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.